M

Mirum Pharmaceuticals
D

MIRM

44.760
USD
1.30
(2.98%)
Market Closed
Volume
14,943
EPS
-1
Div Yield
-
P/E
-22
Market Cap
2,148,685,090
OverviewSignalsIdeasNews
Related Instruments
    A
    ARVN
    -2.440
    (-9.78%)
    22.500 USD
    B
    BCYC
    -0.800
    (-3.54%)
    21.770 USD
    B
    BHAT
    -0.01250
    (-6.17%)
    0.19000 USD
    B
    BHVN
    -4.260
    (-8.76%)
    44.390 USD
    C
    CRVS
    -0.31000
    (-3.64%)
    8.21000 USD
    K
    KURA
    -0.560
    (-3.40%)
    15.920 USD
    M
    MGTA
    0
    (0%)
    0.000000 USD
    O
    OPRA
    -0.080
    (-0.44%)
    18.250 USD
    R
    RNLX
    0.00200
    (1.03%)
    0.19700 USD
    More
News

Title: Mirum Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.